The Food and Drug Administration (FDA) has posted a discontinuation notice for Ocufen (flurbiprofen sodium ophthalmic solution; Allergan) 0.03% and its authorized generic. 

Ocufen contains flurbiprofen sodium, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the inhibition of intraoperative miosis. The drug’s mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential in the biosynthesis of prostaglandins. Prostaglandins have been shown to be mediators of certain kinds of intraocular inflammation

Related Articles

 Allergan has made a business decision to permanently discontinue manufacturing the branded, authorized generic, and a repackaged version of the branded drug. The affected NDCs are #11980-801-03, 60758-910-03, and 42254-023-025, respectively.

For more information call (800) 678-1605 or visit